"Circulating Tumor DNA" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
DNA released from tumor cells that is found circulating in PLASMA; SERUM; or other BODY FLUIDS.
| Descriptor ID |
D000074141
|
| MeSH Number(s) |
D13.444.154.500 D13.444.308.425.500
|
| Concept/Terms |
Circulating Tumor DNA- Circulating Tumor DNA
- DNA, Circulating Tumor
- Tumor DNA, Circulating
- Cell-Free Tumor DNA
- Cell Free Tumor DNA
- DNA, Cell-Free Tumor
- Tumor DNA, Cell-Free
|
Below are MeSH descriptors whose meaning is more general than "Circulating Tumor DNA".
Below are MeSH descriptors whose meaning is more specific than "Circulating Tumor DNA".
This graph shows the total number of publications written about "Circulating Tumor DNA" by people in this website by year, and whether "Circulating Tumor DNA" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 4 | 0 | 4 |
| 2020 | 6 | 1 | 7 |
| 2021 | 6 | 0 | 6 |
| 2022 | 7 | 0 | 7 |
| 2023 | 5 | 0 | 5 |
| 2024 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Circulating Tumor DNA" by people in Profiles.
-
Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non-Small Cell Lung Cancer. JCO Precis Oncol. 2024 Dec; 8:e2400373.
-
Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations. Sci Rep. 2024 07 08; 14(1):15744.
-
LABS: linear amplification-based bisulfite sequencing for ultrasensitive cancer detection from cell-free DNA. Genome Biol. 2024 06 14; 25(1):157.
-
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precis Oncol. 2024 May; 8:e2300531.
-
Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid. Oncogene. 2024 Jun; 43(24):1877-1882.
-
Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. J Am Coll Surg. 2024 Jun 01; 238(6):1013-1020.
-
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes. JCO Precis Oncol. 2023 09; 7:e2300118.
-
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096.
-
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4.
-
Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. Ann Surg. 2023 12 01; 278(6):925-931.